- myelodysplastic syndromes (MDS)
- myeloproliferative neoplasms (MPN)
REBLOZYL® (luspatercept-aamt) is the first erythroid maturation agent (EMA) approved by the US Food and Drug Administration and European Union for the treatment of anemia in adult patients with myelodysplastic syndromes (MDS) who have been failed by an erythropoiesis-stimulating agent (ESA) or are unlikely to respond to an ESA, and are requiring transfusions of 2 or more red blood cell (RBC) units over 8 weeks. The drug is thought to work by decreasing the level of certain proteins that inhibit growth of red blood cells in the bone marrow. The approval is specifically for patients with myelodysplastic syndromes with ring sideroblasts (MDS-RS) or myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). The benefit of luspatercept-aamt in other subtypes of MDS is unclear, and the approval does not extend to other MDS subtypes.